All posts by admin

generic bariatric photo2



Secondo un articolo pubblicato sul Journal of American College of Surgeons, nei centri Accademici degli Stati Uniti, l’intervento laparoscopico di gastrectomia verticale (Sleeve gastrectomy) ha ormai ampiamente sostituito, come procedura bariatrica, il bendaggio gastrico

The study examined the popularity of procedures between October 1 2008 and September 30 2012. It found that by 2012, gastric banding made up 4.8% of all bariatric operations performed in US academic hospitals, a drop from 23.8% four years earlier. Over the same time period, sleeve gastrectomy rose from 0.9% to 36.3%.

Despite remaining the most popular operation, the number of laparoscopic gastric bypasses also decreased over the same period, from 66.8% of all operations in the fourth quarter of 2008 to 56.4% in the third quarter of 2012. The number of open gastric bypasses continued to decline, from 8.6% in 2008 to 3.2% in 2012.

The paper took data from the University HealthSystem Consortium Clinical Database, which collects data from all US academic health centres and affiliate community hospitals. It included data from 60,738 patients.

The authors say that it is the first paper to demonstrate the national trend in the increased use of laparoscopic sleeve gastrectomy in the USA. However, they note that their data did not include operations performed in private medical centres, which means that the numbers reported may not be completely accurate as a picture of bariatric surgery across the country.

The paper notes a number of factors which potentially led to the speedy acceptance of sleeve gastrectomy as a primary operation, at the expense of gastric bands – most notably, the support of the operation as a primary procedure by the ASMBS.

Other factors included the sleeve gastrectomy being found to engender greater weight loss than the gastric band; the willingness of third-party payors to fund the operation; and the perception that failed gastric bands were leading to an unacceptably high rate of explantation.

The paper also published the number of centres performing each type of operation, finding that while the number of centres performing bariatric procedures remained steady, the number of centres performing sleeve gastrectomy had risen by late 2012 to the point where there were over 80 centres identified as performing the operation in the sample, matching the number of centres performing gastric bypass. Conversely, the number of centres performing gastric banding dropped from almost 60 in 2010 to just over 20 in 2012.

Friday, March 1, 2013 
Pete Myall – Online editor, Bariatric News
Leggi di più

L`American Medical Association (AMA) riconosce ufficialmente l`Obesità come “malattia”


The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) commends the American Medical Association (AMA) on its announcement officially recognizing obesity as a disease.

“The AMA’s announcement is a tremendous step forward in legitimizing the severity of the obesity epidemic in our nation,” said Dr. Gerald Fried, SAGES President. “AMA’s decision will increase coverage and patient access to necessary treatment options for the disease, including weight-loss surgery, which  is the most effective treatment for morbid obesity, producing durable weight loss, improvement or remission of comorbid conditions, and longer life.”

SAGES 2013The United States has experienced a steady rise in obesity prevalence over the last 20 years and has the highest national rate of obesity. At the turn of the millennium, nearly two-thirds of Americans were overweight or obese, and almost 5% were morbidly obese [1]. This trend is ominous, because morbid obesity predisposes patients to comorbid diseases which affect nearly every organ system. These include: type 2 diabetes, cardiovascular disease, hypertension, hyperlipidemia, hypoventilation syndrome, asthma, sleep apnea, stroke, pseudotumor cerebri, arthritis, several types of cancers, urinary incontinence, gallbladder disease, and depression [2-4]. Obesity shortens life expectancy [5], with increasing body mass index (BMI) resulting in proportionally shorter lifespan [6].

According to SAGES Bariatric Group, Co-Chaired by Dr. Marian Kurian and Dr. Kevin Reavis, “From a purely medical standpoint, AMA’s move will provide primary care physicians with the diagnostic license to specifically treat obesity, alongside other co-morbidities, and to also prescribe necessary wellness and prevention programs which will go a long way toward treating the disease, improving quality of life and increasing life expectancy.”

  1. Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and Trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727
  2. Must A, Spadano J, Coakley EH et al (1999) The disease burden associated with overweight and obesity. JAMA 282(16):1523- 1529
  3. Overweight, obesity, health risk: National Task Force on the prevention and treatment ofobesity (2000) Arch Intern Med 160:898-904
  4. North American Association for the study of obesity (NAASO), theNational Heart (1998) Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health, Bethesda, MD, NIH publication 98-4083
  5. Mizuno T, Shu IW, Makimura H, Mobbs C (2004) Obesity over the life course. Sci Aging Knowledge Environ 2004(24): re4 (ISSN 1539-6150)
  6. Fontaine KR, Redden DT, Wang C et al (2003) Years of life lost due to obesity.
    JAMA 289(2):187-193

SAGES has been at the forefront of best practices in laparoscopic surgery by researching, developing and disseminating the guidelines and training for standards of practice in surgical procedures. SAGES Guidelines for Clinical Application of Laparoscopic Bariatric Surgery,  were issued in 2008 and are a series of systematically developed statements to assist physicians’ and patients’ decisions about the appropriate use of laparoscopic surgery for obesity.

Guidelines are available at SAGES website – Guidelines for Clinical Application of Laparoscopic Bariatric Surgery.

Leggi di più



Secondo i ricercatori della University of East Anglia, l’Università di Manchester e l’Università di Aberdeen, i pazienti sottoposti a chirurgia bariatrica dimezzano il rischio di avere un arresto cardiaco.
Lo studio, pubblicato sulla rivista International Journal of Cardiology, ha esaminato i dati di quattordici studi che hanno coinvolto più di 29.000 pazienti sottoposti a Chirurgia bariatrica. I risultati sono impressionanti: la mortalità è stata ridotta del 40% e gli attacchi di cuore, in particolare, sono diminuiti della metà, rispetto alle persone obese, che non hanno subìto un intervento chirurgico.

The researchers said that they believe the is the first comprehensive review of the impact of surgery on heart disease, stroke and death.

“We looked at the outcomes for patients who undergo bariatric surgery, and compared them to figures for obese people who had not received surgery,” said Senior author, Dr Yoon Loke from UEA’s Norwich Medical School. “We saw that surgery was potentially life-saving and could lower the risk of having a heart attack and stroke by almost 50 per cent.”

The mean age of participants was 48 years old, and 30 per cent of participants were male. The original studies were carried out the North America, Europe and Australia, and patients were followed-up from two years to 14 years.

After conducting a literature search, they identified 14 studies that met the inclusion criteria, and this included 29,208 patients who underwent bariatric surgery and 166,200 non-surgical controls (mean age 48 years, 30% male, follow up period ranged from 2 years to 14.7 years).

They found that compared to nonsurgical controls, there was more than 50% reduction in mortality amongst patients who had bariatric surgery (OR 0.48 95% CI 0.35–0.64, I2=86%, 14 studies). In pooled analysis of four studies with adjusted data, bariatric surgery was also associated with a significantly reduced risk of composite cardiovascular adverse events (OR 0.54 95% CI 0.41–0.70, I2=58%).

Bariatric surgery was also associated with significant reduction in specific endpoints of myocardial infarction (OR 0.46 95% CI 0.30–0.69, I2 = 79%, four studies) and stroke (OR 0.49 95% CI 0.32–0.75, I2 = 59%, four studies).

“Obesity is a worldwide problem with significant consequences on individuals and society. It is associated with heart disease, type 2 diabetes, many cancers, and a shorter life expectancy,” added Loke. “The latest (UK) government figures from 2011 show that obesity affects about one in four people in the UK and this figure is growing. During 2011-12, the NHS reported 11,736 hospital admissions due to obesity, which represents an 11-fold increase compared to the 1,019 admissions in 2001-02.

“These findings suggest that surgery should be seriously considered in obese patients who have a high risk of heart disease. This is the right time for a large, high-quality trial of bariatric surgery in the NHS to confirm the potential benefits.”

Owen Haskins – Editor in chief, Bariatric News


Leggi di più


Il “Journal of Hepatology”  (Volume 60, Issue 2 , Pages 377-383,  febbraio 2014) ha pubblicato uno studio in relazione agli effetti della chirurgia bariatrica sulla sensibilità all’insulina epatica, che risulta sensibilmente migliorata già dopo sei mesi dall’intervento chirurgico. Detti effetti metabolici sono stati accompagnati da una marcata riduzione del volume epatico e del contenuto di grassi.


Background & Aims
Bariatric surgery reduces weight and improves glucose metabolism in obese patients. We investigated the effects of bariatric surgery on hepatic insulin sensitivity.

Twenty-three morbidly obese (nine diabetic and fourteen non-diabetic) patients and ten healthy, lean control subjects were studied using positron emission tomography to assess hepatic glucose uptake in the fasting state and during euglycemic hyperinsulinemia. Magnetic resonance spectroscopy was performed to measure liver fat content and magnetic resonance imaging to obtain liver volume. Obese patients were studied before bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) and six months after surgery.

Insulin-induced hepatic glucose uptake was increased by 33% in non-diabetic and by 36% in diabetic patients at follow-up compared with baseline, but not totally normalized. The liver fat content was reduced by 76%, liver volume by 26% and endogenous glucose production by 19% in non-diabetic patients. The respective changes in diabetic patients were 73%, 24%, and 25%. Postoperatively, liver fat content and endogenous glucose production were almost normalized to lean controls, but liver volume remained greater than in control subjects.

This study shows that bariatric surgery leads to a significant improvement in hepatic insulin sensitivity: insulin-stimulated hepatic glucose uptake was improved and endogenous glucose production reduced when measured, six-months, after surgery. These metabolic effects were accompanied by a marked reduction in hepatic volume and fat content. Overall, the gain in hepatic insulin sensitivity in diabetic patients was quite similar to non-diabetic patients for the same weight reduction.

Abbreviations: BS, bariatric surgery, T2DM, type 2 diabetes, EGP, endogenous glucose production, HGU, hepatic glucose uptake, VLCD, very-low-calorie diet, PET, positron emission tomography, 18F-FDG, 18F-fluorodeoxyglucose, MRI, magnetic resonance imaging, SG, sleeve gastrectomy, RYGB, Roux-en-Y gastric bypass, OGTT, oral glucose tolerance test, MRS, magnetic resonance spectroscopy, LFC, liver fat content, HbA1c, glycosylated haemoglobin, hs-CRP, high-sensitivity C-reactive protein, IL-6, interleukin-6, IL-8, interleukin-8, MCP-1, monocyte chemotactic protein-1, GLP-1, glucagon-like peptide-1


Leggi di più
England map3


Map of England showing obesity % prevelence                 (Source:


New data published by Public Health England (PHE) has confirmed that 64% of adults are overweight or obese. The data also shows for the first time the considerable variation in the numbers of people who are overweight or obese in different parts of England, as well as the extent of the challenge many local authorities and the local National Health Service face.

However, the rate of  increase in overweight and obese adults has slowed in recent years and in children, levels are stabilising. However, welcome though this is, given the health problems associated with being overweight or obese there are no grounds for complacency.

“Overall health problems associated with being overweight or obese cost the NHS over £5 billion each year,” said Professor Kevin Fenton, Director of Health and Wellbeing at PHE. “There is no silver bullet to reducing obesity; it is a complex issue that requires action at individual, family, local and national levels.

We can all play our part in this by eating a healthy balanced diet and being more active.”

The report shows that Copeland in West Cumbria is the local authority with the greatest obese population area in England, where 75.9% of the population are classed as overweight or obese. The North East is the region with the largest obese population with 68% of the population are overweight, followed by the West Midlands at 65.7%.

By local authority

1. Copeland in west Cumbria (75.9% are overweight or obese)

2. Doncaster in South Yorkshire (74.4%)

3. East Lindsey in Lincolnshire (73.8%)

4. Ryedale in North Yorkshire (73.7%)

5. Sedgemoor in Somerset (73.4%)

6. Gosport in Hampshire (72.9%)

7. Castle Point in south Essex (72.8%)

8. Bolsover in Derbyshire (72.5%)

9. County Durham (72.5%)

10. Milton Keynes (72.5%)

By county

1. Cumbria (68.3%)

2. Lincolnshire (68.2%)

3. North Yorkshire (67.9%)

4. Staffordshire (67.9%)

5. Northamptonshire (67.5%)

6. Essex (67.3%)

7. Derbyshire (66.9%)

8. Nottinghamshire (66.4%)

9. Norfolk (65.7%)

10. Worcestershire (65.5%)

By region

1. North-east (68%)

2. North-west (66%)

3. West Midlands (65.7%)

4. East Midlands (65.6%)

5. Yorkshire and the Humber (65.4%)

6. East of England (65.1%)

7. South-east (63.1%)

8. South-west (62.7%)

9. London (57.3%)

The figures are based on adjusted, self-reported height and weight measurements collected via questions in the Active People Survey by Sport England since January 2012.

Owen Haskins – Editor in chief, Bariatric News

Leggi di più
Prof. Dott. Francesco Rubino



It what is thought to be a world first, King’s College Hospital and King’s College London (part of King’s Health Partners Academic Health Sciences Centre, AHSC), have established the first university chair in metabolic surgery and Professor Francesco Rubino has become the world’s first Professor of this surgical discipline.

The appointment of Professor Rubino demonstrates the growing importance and prevalence of metabolic and weight-loss surgery world-wide, as well as reflecting the trend towards more sophisticated and scientific advances in bariatric surgery.

“I am thrilled about the opportunity to join King’s and help advance the Institution’s goal of developing innovative strategies for understanding and treating diabetes and obesity,” said Professor Rubino. “The establishment of a chair in metabolic and bariatric surgery demonstrates King’s visionary leadership and ambition to shape clinical practice and future research in one of the most fascinating fields of modern medicine.”

His role at King’s will include developing a multidisciplinary model of care, shaped around the aim of reducing cardiovascular risk and long-term risk of mortality associated with diabetes and obesity. A specific research goal of new programme will also be trying to discover the exact mechanisms by which surgical procedures improve or resolve diabetes. This knowledge can help identify new targets for the development of future therapies of curative intent and may possibly shed light on the root causes of the disease

“Professor Rubino’s appointment is an exciting development for our AHSC. He is a pioneer who has led diabetes surgery as an entirely new surgical field – one in which gastrointestinal operations can be performed to directly treat diabetes, not just as a by-product of weight-loss surgery,” said Professor Sir Robert Lechler Executive Director, King’s Health Partners. “This is a significant milestone in the development of King’s Health Partners’ mission to understand and treat the diabetes and obesity pandemic, and I am in no doubt that Professor Rubino’s unique expertise will benefit the 90,000 people diagnosed with diabetes across south London and beyond.”

Rubino’s pioneering research provided the first experimental evidence that bariatric surgery can improve diabetes independently on weight loss. He also developed new surgical procedures and contributed to conceptually transform bariatric surgery from a mere weight loss therapy into a surgical approach aimed at treating diabetes, obesity and metabolic disease, a novel surgical discipline that goes under the name of metabolic surgery.

He was one of the principal organisers of the Rome’s Diabetes Surgery Summit in 2007 and also directed the 1st and 2nd World Congress on Interventional Therapies for Type 2 Diabetes in 2008 and 2011. His clinical expertise includes laparoscopic bariatric and metabolic procedures such as gastric bypass, sleeve gastrectomy, gastric banding and other interventions on the upper digestive system.

Before joining King’s, Professor Rubino worked at Catholic University of Rome, Italy, Hopital Civil, Strasbourg, France and served as Chief of Gastrointestinal Metabolic Surgery at Weill Cornell Medical College/New York Presbyterian Hospital in New York, USA.

Thursday, January 23, 2014 – 14:37Owen Haskins – Editor in chief, Bariatric News

Leggi di più

Il giudice di MasterChef Usa Graham Elliott si è sottoposto all`intervento di Sleeve Gastrectomy


Il giudice di MasterChef Usa Graham Elliott all’età di 36 anni e 180 chili ha deciso di fare qualcosa per sè e per la sua famiglia, si è sottoposto all’intervento di Sleeve gastrectomy, per rimuovere circa l’80 % dello stomaco, come dichiarato in una recente intervista a People e a Vanity Fair. Ha perso 60 chili in pochi mesi. Si possono vedere le foto del “prima” e “dopo” l’intervento.

MasterChef Judge Graham Elliott has a career that some would envy. He gets paid to taste gourmet dishes created by aspiring chefs. On an almost daily basis, he gives his palate quite the workout by experiencing a variety of heavenly foods; rich, creamy sauces, French truffles, Foie gras, lobster, Kobe beef and other delicious dishes that any food connoisseur would love to try. But the very career he loves and chose has been taking it’s toll on his health. At the age of 36, the 6’2 chef found himself tipping the scales at 400 pounds and last week, the father of three decided to do something about it. He underwent the sleeve gastrectomy which removes about 80 percent of the stomach.

Elliott admits to having struggled with his weight all his life but he has a family now and his priorities have changed. He was finding it hard to play with his sons, and to get in and out of the car, or to tie his shoes.

“This is what I need to do for my family,” the chef says of his decision to have weight loss surgery and in a recent interview with People. “What’s going to make me healthy is the most important thing right now so I can enjoy my kids and be around long enough to see them grow up.”

Elliot’s co-judges of MasterChef Gordon Ramsay and Joe Bastianich have also been motivating factors in his decision to get healthy. They have been supportive and have encouraged him to lose the weight and to change his life. Ramsey and Bastianich both run marathons and Elliott’s biggest goal is to be able to start running. “I get inspiration from both these guys.”

Elliott, who at 27 became the youngest Four Star Chef to be named in any major U.S. city, says that his profession also played a major consideration in his decision to have surgery and specifically the sleeve gastrectomy. In a consultation with his doctor, they both agreed the sleeve was best suited for Elliott. The procedure will not restrict what foods he eats and he will be able to still taste and try foods as a MasterChef judge. The culinary wizard had been thinking about having weight loss surgery since 2005 but it wasn’t until this year that he ultimately made the decision to move forward.

“It’s like I’m somebody who is way past their prime and that shouldn’t be the case at 36. Throw in gout and high blood pressure and the history of strokes and heart attacks in my family … this is something that has to happen.”

The acclaimed chef is looking forward to a healthier future and a lifestyle that his dramatic weight loss will offer and you can bet that his kids are pretty excited about that.

by Tammy J. Colter
July 22, 2013

Vanity Fair
16 gennaio 2014

Ha perso 60 chili in pochi mesi, da 180 a 120. Graham Elliot, chef a capo di un impero della ristorazione in America, noto al grande pubblico come giudice di MasterChef Usa (gli altri sono Gordon Ramsay e Joe Bastianich), è irriconoscibile nelle foto del «prima» e «dopo», che ha postato su Twitter. Un miracolo reso possibile grazie a una gastrectomia (operazione chirurgica che prevede l’asportazione di parte dello stomaco), che gli ha ridato le forze per iniziare una nuova vita più sana e sportiva: ora corre, con l’obiettivo dichiarato di partecipare alla maratona di Chicago.


Leggi di più







Ci sono una serie di ormoni peptidici come l’apelina, l’orexina, la grelina e la leptina che rivestono un ruolo importante nell’obesità fisiopatologia, nelle alterazioni metaboliche associate e nel bilancio energetico.

I ricercatori dello studio del Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Université Laval, Québec, Canada, e il Dipartimento di Fisiologia, Università Medica di Re Giorgio, Lucknow, in India, ha rilevato che l’aumen to post-operatorio dei livelli di orexina si mantiene per tutto il periodo di follow-up (un anno). Questo studio fornisce preziose informazioni sui potenziali biomarcatori per il targeting in terapia.

Owen Haskins – Editor in chief, Bariatric News

An acute post-bariatric surgery increase in orexin levels is associated with rapid improvement in glucose metabolism, according to a study published online in the journal PlosOne.

The study researchers from the Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Université Laval, Québec, Canada, and the Department of Physiology, King George’s Medical University, Lucknow, India, said that this post-operative increase in orexin levels is associated with the maintenance of increased orexin throughout the one-year follow-up period, adding that the study provides valuable information on potential biomarkers for targeting in therapy.

There are a number of peptide hormones such as apelin, orexin, ghrelin and leptin that play a role in obesity pathophysiology, associated metabolic alterations and energy balance.

Orexin (or hypocretin) is a neurotransmitter that regulates arousal, wakefulness, and appetite. It is known to increase the craving for food and correlates with the function of the substances that promote its production.

Orexin-producing cells have been shown to be inhibited by leptin (through the leptin receptor pathway), but are activated by ghrelin and hypoglycemia (glucose inhibits Orexin production). Orexin is a very important link between metabolism and sleep regulation.

Orexin levels have also been shown to increase during low energy conditions and decrease when energy levels are high, therefore soaring Orexin levels trigger wakefulness, vigilance and hunger. In addition to promoting wakefulness and regulating food intake, orexin-A has been implicated in diabetes mellitus and obesity.

As a result, the researchers investigated the short- and long-term (up to one year) changes in plasma orexin levels and the association with metabolic changes following biliopancreatic diversion with duodenal switch (BPD-DS) bariatric surgery.


Results for orexin levels for all 76 subjects over the one year time indicate a significant change overall (Figure 1). However, when subjects were evaluated individually, there was a range in orexin response: orexin increased (Orexin-INC) in some subjects, in other subjects orexin remained unchanged and in other subjects, orexin decreased (Orexin-DEC).

Figure 1. Plasma orexin levels (ng/ml) pre-operative (baseline; BSL) and post-operative at one and five days (D), six and 12 months (M) following BPD-DS bariatric surgery.

The orexin changes occurred as early as one day post-op, and remained consistent within each subject, such that the % change at one day correlated closely with % change at five days (r=0.526, p<0.0001), six months (r=0.410, p=0.0006) and 12 months (r=0.410, p=0.0006). Baseline plasma Orexin levels were not significantly different between the two groups (3.31±0.31 vs. 2.92±0.28ng/mL).

Within the first few days following the surgery (up to five days), there was no significant change in body composition between Orexin-INC and Orexin-DEC groups. However, at six months, there were marked decreases in BMI in both groups by 25–27%, reflecting a decrease in both fat mass (22–24%) and lean mass, but with comparable changes in both groups. This was also true at 12 months, with further decreases in BMI (36% to 37%) and percent body fat (average 36%) although the patient weight status still remained within the obese range.

Out of 33 Orexin-DEC subjects, 15 (45%) were diabetic compared with 11 (55%) patients in the Orexin-INC group. Post-operatively, there was a marked reduction in the diabetic status, but there was no difference between groups. However, although changes in weight and % fat mass were comparable between both groups, the response to various glucose and lipid parameters was not the same.

In the Orexin-DEC group at baseline, 15 (45%) were being treated with lipid lowering therapy, while 10 (50%) patients were being treated in the Orexin-INC group. Postoperatively, there was a reduction in those being treated, which was comparable between the two groups. However, there were both acute (one and five days) and long-term (six and 12 months) changes in lipid profiles, with overall greater changes in the Orexin-INC group relative to the Orexin-DEC group.

Over the long-term (at six months and 12 months), there was a significant continued reduction of fasting cholesterol, triglyceride and LDL-cholesterol, again with greater changes in the Orexin-INC group, while HDL-C increased (Figure 2).

Figure 2. Rapid and long-term improvement in lipid profile after BPD-DS bariatric surgery.

The researchers write that the major findings from the study include; early acute changes in orexin levels prior to weight loss, changes are present in some but not all patients, and early orexin changes were maintained consistently within subjects throughout the observation period (one year).

In addition, they note that comparable long-term weight decreases, the early changes in orexin are associated with differential improvements in lipid and glucose profiles throughout the one-year postoperative period.


  • Pubblicato il: 6 Gennaio 2014
  • DOI: 10.1371/journal.pone.0084803



Leggi di più
preparation for operation

Master in Chirurgia dell`Obesità Patologica – Università di Roma Tor Vergata

TorvergataE’ attivo presso l’Università di Roma Tor Vergata il Master in Chirurgia dell’Obesità Patologica.

Chirurgia dell`obesità patologica

Master di secondo livello della Facoltà di Medicina e Chirurgia

Durata 2 anni – crediti 60 a.a. 2013-2014


La domanda di ammissione va effettuata entro e non oltre il 09/01/2014

in modalità on-line connettendosi al
sito d’Ateneo , selezionare AREA STUDENTI e poi nell’ordine: A) CORSI POSTLAUREAM
Facoltà di Medicina e Chirurgia – Codice Corso PLS

Si può scaricare  il bando dell’ a.a. 2013-2014, in formato PDF, cliccando sempre sul link:

 Nell’anno accademico 2013/2014 è istituito e attivato, presso la Facoltà di Medicina e Chirurgia, il Master Universitario di II livello in Chirurgia dell’Obesità Patologica, ai sensi dell’art. 9 del d.m. 270/2004.

Coordinatore: Prof. Paolo Gentileschi

Il Master ha lo scopo di:

  • implementare la diffusione e lo sviluppo della Chirurgia Bariatrica;
  • supplire alla mancanza di insegnamento di tale disciplina nelle scuole di specializzazione;
  • incrementare il numero di Chirurghi specialisti in tale materia;

Al termine del Master i partecipanti avranno appreso le nozioni e gli strumenti tecnici per la gestione autonoma degli aspetti clinici ed organizzativi connessi all’attività della chirurgia bariatrica.
E’ rivolto a laureati in Medicina e Chirurgia. Non è prevista la presenza di uditori. Non è possibile frequentare singoli moduli.

Per informazioni gli interessati potranno rivolgersi a:

Leggi di più